Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonyf NVXPAR:MLBON 12 PB Ratio is 0.55 as of Aug. 02, 2026, which is 81% below its 10-year median of 2.87. GuruFocus rates XPAR:MLBON with a GF Score™ of 12/100 and a GF Value™ of €8.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Bonyf NV ranks better than 91.5% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-02), Bonyf NV's share price is €2.48. Bonyf NV's Book Value per Share for the quarter that ended in Dec. 2024 was €4.49. Hence, Bonyf NV's PB Ratio of today is 0.55.
Good Sign:
Bonyf NV stock PB Ratio (=0.55) is close to 5-year low of 0.55.
The historical rank and industry rank for Bonyf NV's PB Ratio or its related term are showing as below:
XPAR:MLBON'
s PB Ratio Range Over the Past 10 Years
Min: 0.55 Med: 2.87 Max: 26.32
Current: 0.55
During the past 5 years, Bonyf NV's highest PB Ratio was 26.32. The lowest was 0.55. And the median was 2.87.
XPAR:MLBON's PB Ratio is ranked better than 91.5% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.06
vs XPAR:MLBON: 0.55
During the past 12 months, Bonyf NV's average Book Value Per Share Growth Rate was -1.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 111.40% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Bonyf NV was 111.40% per year. The lowest was 98.00% per year. And the median was 104.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bonyf NV PB Ratio Related Terms
Bonyf NV PB Ratio Historical Data
* Premium members only.
The historical data trend for Bonyf NV's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV PB Ratio Chart
Bonyf NV Annual Data
Trend
Dec19
Dec20
Dec22
Dec23
Dec24
PB Ratio
0.00
0.00
1.90
2.64
4.01
Bonyf NV Semi-Annual Data
Dec19
Dec20
Dec22
Dec23
Dec24
PB Ratio
0.00
0.00
1.90
2.64
4.01
XPAR:MLBON vs ISRG, BDX, MDLN: PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bonyf NV's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonyf NV PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonyf NV's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bonyf NV's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Bonyf NV's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bonyf NV (XPAR:MLBON) has a PB Ratio of 0.55 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bonyf NV and its competitors. This is 81% below median its historical median of 2.87. Over the past decade, Bonyf NV's PB Ratio has ranged from 0.55 to 26.32. According to the industry distribution chart, Bonyf NV ranks #67 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 8.5%.
Is Bonyf NV's PB Ratio too high?
Bonyf NV's current PB Ratio of 0.55 is 81% below median its 10-year median of 2.87. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 26.32. The Medical Devices & Instruments industry median PB Ratio is 2.06. Bonyf NV's value of 0.55 is 73.3% below this industry median. Based on the distribution chart, Bonyf NV ranks #67 out of 788 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonyf NV has a GF Score™ of 12/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonyf NV's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonyf NV ranks #67 out of 788 companies for PB Ratio. This places Bonyf NV in the top 9% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.06. Bonyf NV's value of 0.55 is 73.3% below this benchmark. Historically, Bonyf NV's own PB Ratio has ranged from 0.55 to 26.32 over the past decade. While the company's 10-year median is 2.87 vs. the industry median of 2.06, Bonyf NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.06, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonyf NV's current PB Ratio of 0.55 is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bonyf NV and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonyf NV's current PB Ratio is 0.55, which is 81% below median its own 10-year median of 2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonyf NV stock overvalued right now?
Based on GuruFocus' analysis, Bonyf NV (XPAR:MLBON) is currently considered Possible Value Trap. The stock's GF Value™ is €8.61, compared to a current price of €2.48 — trading 71.2% below its estimated fair value. The current PB Ratio is 0.55, which is 81% below median its 10-year median of 2.87 and 73.3% below the Medical Devices & Instruments industry median of 2.06. Bonyf NV's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bonyf NV (XPAR:MLBON), the current PB Ratio is 0.55 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonyf NV (XPAR:MLBON) Overvalued in 2026?
Based on GuruFocus' analysis, Bonyf NV stock appears to be undervalued.
The current stock price of €2.48 is trading 71.2% below its estimated GF Value™ of €8.61.
GuruFocus considers Bonyf NV to be Possible Value Trap.
Key valuation signals for XPAR:MLBON:
PB Ratio: 0.55 (81% below median its 10-year median of 2.87)
GF Value™: €8.61 vs. price of €2.48 (71.2% below fair value)
Industry Position: 73.3% below the Medical Devices & Instruments median (#67 of 788)
No single metric tells the full story. See the XPAR:MLBON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonyf NV specializes in developing, producing and selling cutting-edge oral & dental care products. It is a forward-thinking company committed to revolutionizing oral care through innovation and research.
12GF Score
Get the complete analysis for XPAR:MLBON
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBON has been successfully added to your 
